Skip to main content
OpenTrials
Completed

NCT Number: NCT03327168

Adenosine and A2A Receptors in Human Brown Adipose Tissue

This study investigates the significance of adenosine and A2A receptors in human brown adipose tissue (BAT) in vivo. Using positron emission tomography (PET), perfusion and the density of A2A receptors will be measured in supraclavicular BAT and other tissues in healthy men. The investigators hypothesize, that adenosine can activate BAT, and that adenosine A2A receptor density changes when BAT is activated by cold exposure.

Understanding the mechanisms of BAT activation and the role of endocannabinoids in humans is important and beneficial in fighting against the epidemic of obesity and diabetes.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–40 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

About this study

Adenosine is a purine nucleoside released locally in BAT when noradrenaline and ATP are released from sympathetic nerves. Recently it was found that adenosine activates murine and human brown adipocytes, and recruits beiging of white fat via adenosine A2A receptors (A2AR). Furthermore, studies with mice have shown improvements in glucose homeostasis after administration of A2AR agonists.

In this study the investigators use the PET radiotracer [15O]-H2O to quantify perfusion of BAT, white adipose tissue (WAT) and muscle in three conditions: room temperature, cold exposure and intravenous infusion of adenosine. Another PET radiotracer [11C]TMSX is used to quantify adenosine A2A receptor density of BAT, WAT and muscle in room temperature and during cold exposure.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male sex
  • BMI 20 - 28 kg/m2
  • Age: 18- 40 years
  • Normal OGTT
  • Healthy, no regular medication

Exclusion criteria

  • BMI < 20 kg/m2 or BMI > 28 kg/m2
  • Low or high blood pressure
  • Asthma or other obstructive lung disease
  • Sick sinus syndrome, prolonged QT-interval, or any heart disease
  • Any chronic disease that could affect the study outcome, including diabetes
  • Mental disorder or poor compliance
  • Eating disorder or excessive use of alcohol, tobacco smoking or drug use
  • Past dose of radiation
  • Any other condition that in the opinion of the investigator could create a hazard to the subject safety, endanger the study procedures or interfere with the interpretation of study results

Treatment and study plan

Adenosine

Drug

Intravenous infusion of adenosine (0.14 mg/kg) is administered for 5 minutes during PET/CT scan.

Other names: Adenocor

Cold exposure

Other

Controlled cold exposure is performed before and during PET/CT scan.

Primary outcomes

  1. BAT perfusion

    Time frame: Effect within 10 minutes

    Perfusion of BAT with [15O]-H2O PET-CT

  2. A2A receptor density in BAT

    Time frame: Effect within 3 hours

    Density of A2A receptors in BAT measured with [11C]-TMSX PET/CT

Sponsors and collaborators

Lead sponsor

Turku University Hospital

Other Gov

Collaborators

  • University of Bonn

Registry information

Official study title

Adenosine and A2a Receptors in Human Brown Adipose Tissue (AdenoBAT)

Acronym: AdenoBAT

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Oct 31, 2017
Registry last updated
Nov 6, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.